Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYO7
- Development stage
- Preclinical
- Lead developer
- Myocea
- Modality
- Small Molecules
01
Overview
MYO7 is a preclinical small molecule drug candidate from Myocea being developed for **Spinal Muscular Atrophy** with a skeletal muscle and neuromuscular junction oriented discovery rationale. The program is identified on Myocea's pipeline as an SMA asset targeting **LIM kinase** and **ROCK** signaling, implying intended modulation of cytoskeletal and muscle biology pathways relevant to SMA pathophysiology. No formal clinical data, dose, route, brand name, or more specific mechanism details have been publicly disclosed in the provided source material.
- Other names
- Myocea-LIM kinase-ROCK-small molecule-Spinal Muscular AtrophyMyocea LIM kinase ROCK small molecule for Spinal Muscular Atrophy
Beyond the preview
Go deeper on MYO7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MYO7.